Drug Trials Snapshots: EGATEN | FDA

Drug Trials Snapshots: EGATEN | FDA

Egaten®: An FDA-approved treatment for fascioliasis in the US

What to Know: Egaten, previously available from the CDC by following the Single Patient Investigational New Drug process, is currently available from Novartis. Egaten is the only drug approved in the United States for the treatment of fascioliasis, an infectious disease caused by a flat worm (“fluke”) parasite. More information. 

How to Counsel Your Patients: The recommended dose of Egaten is 2 doses of 10 mg/kg given 12 hours apart for patients 6 years of age and older. The 250 mg tablets are functionally scored and divisible into two equal halves of 125 mg. If the dosage cannot be adjusted exactly, round the dose upwards. Egaten will be provided at no charge to patients.